Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heptares Therapeutics Ltd.

Division of Sosei Group Corp.
www.heptares.com

Latest From Heptares Therapeutics Ltd.

Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea

Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.

Deals M & A

Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation

An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.

Commercial Companies

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Sosei Group Corp.
  • Senior Management
  • Malcolm Weir, PhD, Chmn. & CEO
    Fiona Marshall , PhD, CSO
    Barry Kenny, PhD, Chief Business Officer
    Tim Tasker, MD, VP, Dev. & CMO
    Ali Jazayeri, CTO
  • Contact Info
  • Heptares Therapeutics Ltd.
    Phone: (44) 1707 358 628
    BioPark
    Broadwater Rd.
    Welwyn Garden City, AL7 3AX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register